Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Post-Shutdown Quality Lowdown

Executive Summary

Quality oversight activity began ramping back up after the partial US government shutdown, even as EU oversight activities entered into a Brexit-related slowdown.

You may also be interested in...



The Quality Lowdown: Diversion, Cross-Contamination And PR Mix-Ups

McKesson meets with US FDA over opioid diversion warning letter, while UK MHRA takes risk-based approach to cross-contamination recalls and firm says it’s the other Guardian Pharmacy.

Brexit Won't Impair Pharmacovigilence 'Fundamentals' – DIA Panel

MHRA pharmacovigilance leader says global safety efforts will not lose UK expertise.

Pfizer Eyes Three Oncology Biosimilar Launches In 2019 As Sterile Injectables Problems Persist

Pfizer’s long-standing sterile injectable supply and manufacturing issues pummelled respective sales in the US in 2018. But the US-based multinational is eyeing a string of oncology biosimilar launches in 2019, which could see biosimilar sales tick past US$1 billion.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS124685

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel